Arrowhead Pharmaceuticals Inc (ARWR)

Currency in USD
21.79
+0.61(+2.88%)
Closed·
21.66-0.13(-0.60%)
·
ARWR Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
ARWR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21.0621.82
52 wk Range
9.5727.34
Key Statistics
Prev. Close
21.79
Open
21.06
Day's Range
21.06-21.82
52 wk Range
9.57-27.34
Volume
2.25M
Average Volume (3m)
2M
1-Year Change
-14.25%
Book Value / Share
3.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARWR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.79
Upside
+100.94%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Arrowhead Pharmaceuticals Inc Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Inc SWOT Analysis


Plozasiran's Promise
Arrowhead's lead drug candidate for FCS treatment nears potential FDA approval, showcasing strong Phase 3 results and advantages over competitors
Strategic Pivot
Explore Arrowhead's shift towards cardio-metabolic treatments, allocating 75% of R&D spending to this promising area
Market Valuation
Despite pipeline progress, stock underperforms biotech index. Analysts view current price as attractive, with targets ranging from $42 to $73
Future Horizons
Delve into Arrowhead's innovative integrin-targeting approach, potentially expanding applications in muscle-related disorders and differentiating from competitors
Read full SWOT analysis

Arrowhead Pharmaceuticals Inc Earnings Call Summary for Q3/2025

  • Arrowhead Pharma reported Q3 net loss of $1.26/share, missing $0.86 forecast; revenue at $27.8M vs $53.9M expected
  • Stock declined 1.53% after-hours to $16.06; company maintains strong liquidity with current ratio of 5.15
  • Plodasiran awaiting FDA approval, decision expected November 2025; multiple drug launches anticipated 2025-2028
  • CEO highlighted innovation in 5 areas: hepatocytes, pulmonary, adipose, skeletal muscle, and CNS
  • Analysts project 186% revenue growth for fiscal 2025; company expects milestone payments from Sarepta collaboration
Last Updated: 08/08/2025, 11:36
Read Full Transcript

Compare ARWR to Peers and Sector

Metrics to compare
ARWR
Peers
Sector
Relationship
P/E Ratio
−20.3x−1.2x−0.6x
PEG Ratio
−0.26−0.050.00
Price/Book
5.8x1.7x2.6x
Price / LTM Sales
5.3x8.4x3.3x
Upside (Analyst Target)
81.8%278.7%38.7%
Fair Value Upside
Unlock28.0%5.1%Unlock

Analyst Ratings

10 Buy
5 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 43.79
(+100.94% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-1.26 / -0.86
Revenue / Forecast
27.77M / 53.90M
EPS Revisions
Last 90 days

ARWR Income Statement

People Also Watch

18.07
SRPT
-1.04%
46.03
BMNR
-7.85%
179.20
ALAB
+0.36%
15.230
QBTS
-1.42%
48.250
ASTS
-4.32%

FAQ

What Stock Exchange Does Arrowhead Pharma Trade On?

Arrowhead Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Arrowhead Pharma?

The stock symbol for Arrowhead Pharma is "ARWR."

What Is the Arrowhead Pharma Market Cap?

As of today, Arrowhead Pharma market cap is 3.01B.

What Is Arrowhead Pharma's Earnings Per Share (TTM)?

The Arrowhead Pharma EPS (TTM) is -1.14.

When Is the Next Arrowhead Pharma Earnings Date?

Arrowhead Pharma will release its next earnings report on 30 Nov 2025.

From a Technical Analysis Perspective, Is ARWR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Arrowhead Pharma Stock Split?

Arrowhead Pharma has split 2 times.

How Many Employees Does Arrowhead Pharma Have?

Arrowhead Pharma has 609 employees.

What is the current trading status of Arrowhead Pharma (ARWR)?

As of 28 Aug 2025, Arrowhead Pharma (ARWR) is trading at a price of 21.79, with a previous close of 21.79. The stock has fluctuated within a day range of 21.06 to 21.82, while its 52-week range spans from 9.57 to 27.34.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.